Expertos Invitados





DESTACAN LA UTILIDAD DE MARCADORES GENETICOS Y MOLECULARES PARA PREDECIR COMPLICACIONES DEL TRASPLANTE RENAL

(especial para SIIC © Derechos reservados)
La personalización del tratamiento podría tener consecuencias positivas para los receptores de trasplantes. Ciertos marcadores de rechazo y de enfermedad cardiovascular podrían ayudar a identificar aquellos individuos con riesgo de presentar esas complicaciones y guiar la implementación de medidas preventivas.
varagunam9.jpg Autor:
Mira Varagunam
Columnista Experto de SIIC

Institución:
Royal London Hospital

Artículos publicados por Mira Varagunam
Coautor
Magdi Mohammed Yaqoob* 
MD, FRCP, Royal London Hospital, Londres, Reino Unido*
Recepción del artículo
2 de Agosto, 2006 		Aprobación
24 de Agosto, 2006
Primera edición
11 de Enero, 2007 		Segunda edición, ampliada y corregida
7 de Junio, 2021

DESTACAN LA UTILIDAD DE MARCADORES GENETICOS Y MOLECULARES PARA PREDECIR COMPLICACIONES DEL TRASPLANTE RENAL

Resumen
El trasplante renal no sólo prolonga la supervivencia, sino que además mejora la calidad de vida y mitiga las complicaciones y las molestias secundarias a la insuficiencia renal en etapa terminal. Sin embargo, el rechazo y la enfermedad cardiovascular constituyen aún desafíos fundamentales. El perfeccionamiento del control y el tratamiento individualizado mejorarían los resultados. El objetivo a largo plazo consiste en optimizar las técnicas de detección sistemática empleadas para evaluar el riesgo de ambas complicaciones y que permitirían a un equipo multidisciplinario centrar el tratamiento y las medidas preventivas en aquellos individuos con mayor riesgo. A pesar de que se identificaron los factores de riesgo que sugieren rechazo o enfermedad cardiovascular, éstos no resultan adecuados. Este hecho motiva la búsqueda de marcadores genéticos y proteicos de predicción, que puedan medirse de manera relativamente no invasiva, como la obtención de una muestra de sangre. Las investigaciones recientes demostraron que ciertos marcadores implicados en el proceso inflamatorio pueden aportar información adicional y, por lo tanto, reforzar el valor de predicción al ser combinados con los factores de riesgo tradicionales.

Palabras clave
polimorfismo genético, trasplante renal, enfermedad cardiovascular, rechazo, insuficiencia renal terminal


Artículo completo
(castellano)
Extensión:  +/-9.1 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

MOLECULES AND GENES: UTILITY AS MARKERS OF REJECTION AND CARDIOVASCULAR DISEASE IN RENAL TRANSPLANT PATIENTS

Abstract
Transplantation not only confers a survival advantage, but also improves quality of life and alleviates the complications and discomfort resulting from end stage renal failure. However rejection and cardiovascular disease (CVD) remain major challenges. Better monitoring and individualised therapy would improve outcome. The long term goal is to optimise screening techniques that would assess risk of both these complications and enable the multi disciplinary team to focus therapy and preventative measures on those individuals who have high risk scores. Although there are established risk factors that are indicative of rejection and CVD, these are not adequate. This has led to the search for both genetic and protein predictive markers that could be measured from the relatively non-invasive method of obtaining a blood sample. Recent research has shown that certain markers involved in inflammation can give us additional information, thereby enhancing the predictive value in combination with the established risk factors.

Key words
genetic polymorphisms, renal transplant, cardiovascular disease, rejection, end stage renal failure


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Trasplantes
Relacionadas: Bioquímica, Cardiología, Diagnóstico por Laboratorio, Genética Humana, Inmunología, Medicina Farmacéutica, Medicina Interna, Nefrología y Medio Interno



Comprar este artículo
Extensión: 9.1 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Mira Varagunam, Clinical Transplantation Laboratory, 2nd Floor Pathology and Pharmacy Building, E1 2ES, 80 Newark Street, Whitechapel, Londres, Reino Unido
Bibliografía del artículo
1. Ojo AO, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12(3):589-97.
2. Meier-Kriesche HU, Schold JD. The impact of pretransplant dialysis on outcomes in renal transplantation. Semin Dial 2005; 18:(6)499-504.
3. Ponticelli C. Renal transplantion: Where do we stand today? Nephrol Dial Transplant 2004; 19:2937-2947.
4. Kasiske BL, Guijarro C, Massey ZA, Wiederkerhr MR, Ma JZ. Cardiovasuclar disease after renal transplantation. J Am Soc Nephrol 1996; 7:158-165.
5. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndoromes. Am J Cariol 2001; 88(suppl 1):10K-15K.
6. Russel R. Atherosclerosis - An inflammatory disease. New Eng J Med 1999; 340(2):115-126.
7. Lauzurica R, Pastor MC, Bayes B et al. F2-Isoprostanes in kidney transplant patients: Relationship with inflammatory markers. Transplant Proc 2005; 37:3842-3843.
8. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(suppl3):112-110.
9. Magee CC, Pascual M. Update in renal transplantation. Arch Intern Med 2004; 164:1373-1388.
10. Kreis HA, Ponticelli C. Cause of late allograft loss: Chronic allograft dysfunction, death and other factors. Transplantion 2001; 71(11):SS5-SS9.
11. Kamoun M. Cellular and molecular parameters in human allograft rejection. Clin Biochem 2001; 34:29-34.
12. Kasper M, Rouschop A, Joris J, et al. Pre-transplant plasma and cellular levels of CD44 correlate with acute renal allograft rejection. Nephrol Dial Transplant 2005; 20:2248-2225.
13. Rajakariar R, Jivanji N, Varagunam M et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 2005; 5:1922-1925.
14. Kruger B, Schnitzbauer AA, Boger CA et al. Pretranslplant calcium levels have no predictive value for delayed graft function, long term graft function, cardiovascular events or graft and patient survival in renal transplanation. Transp Proceed 2006; 38:697-700.
15. Boom H, Mallet MJ, De Fijter JW , Paul LC, Bruijn JA, Van ESLA. Calcium levels as a risk factor for delayed graft function. Transplanation 2004; 77:868-873.
16. Varagunam M, Finney H, Trevitt R, Sharples E et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome in kidney transplant recipients. Am J Kid Dis 2004; 43:502-507.
17.Fink JC, Onuigbo MA, Blahut SA et al. Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: A case control study. Am J Kidney Dis 2002; 39:1096-1101.
18. Sankaran D, Asderakis A, Ashraf S et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999; 56:281-288.
19. Asderakis A, Sankeran D, Dyer P et al. Associations of polymorphisms in the human interferon gamma and interleukin 10 gene with acute and chronic kidney transplant outcome: The cytokine effect on transplanatation. Transplantation 2001; 71:674-677.
20. Mytilineos J, Laux G, Gerhard O. Relevance of IL10, TGF b1, TNF and IL4 Ralpha gene polymorphisms in kidney transplantation: A collaborative transplant study report. Am J Transplantaion 2004; 4:1684-1690.
21. Hackstein H, Kluter H, Fricke L, Hoyer J, Bein G. The IL4 receptor alpha chain variant Q576R is strongly associated with decreased kidney allograft survival. Tissue Antigens 1999; 54:471-477.
22. Ligerio D, Sancho MR, Popoila A et al. Impact of donor and recipient cytokine genotypes on renal allograft outcome. Transplant Proc 2004; 36(4):827-829.
23. Shahabzi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV and Harden PN. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13:260-264.
24. Varagunam M, Gupta A, McCloskey DJ et al. Recipient DD ACE genotype is associated with significant progressive chronic renal dysfunction in stable renal allograft recipients.J Am Soc Nephrol 2005; 16:242A.
25. Akcay A, Sezer S, Ozdemir FN et al. Association of the genetic polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction. Transplantation 2004; 78(6):892-898.
26. Suwelack B, Kempkets-Koch M, Hillebrand U, Kobelt V et al. Impact of ACE polymorphism on renal allograft function, blood pressure and proteinuria under ACE inhibiton. Transplantation Proceedings 2002; 34:1763-1766.
27.Rodríguez Moreno A, Sánchez Fructuoso AI, Ridao Cano N et al. Association of the genetic polymorphisms of the renin-angiotensin system with kidney graft long-term outcome: preliminary results. Transplant Proc 2005; 37(9):3716-3717.
28. Slowinski T, Diehr P, Kleemann P et al. No association between renin-angiotensin system gene polymorphisms and early and long term allograft dysfunction in kidney transplant recipients. Nephrol Dial Transplant 2004; 19:2846-2851.
29. Morales JM, Domínguez Gil. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplanation. J Hypertens 2005; 23:1609-1616.
30. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentrations in haemodialysis patients. Am J Kidney Dis 1997; 29:658-668.
31. Fine A. Relevance of C-reactive protein levels in peritoneal dialysis patients: Kidney Int 2002; 61:615-620.
32. Ridker PM, Cushman M, Stamfer MJ, Vijit D. Inflammation, asprin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
33. Wanner C, Zimmerman J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int 2002; 61:S99-S102.
34. Noh H, Lee SW, Kang S et al. Serum C- reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18:387-394.
35. Sezer S, Ozdemir F, Alkay A et al. Post transplant C- reactive protein monitoring predicts chronic rejection and renal allograft survival. Tissue Antigens 2002; 60(6):558-559.
36. Lauzurica R, Pastor C, Bayes B, Hernández JM, Romero R. Pretransplant pregnancy associated plasma protein-A as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events. Transplantation 2005; 80(10):1441-1446.
37. Andreotti F, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 2002; 87:107-112.
38. Girnt M, Kaul H, Sester U, Ulrich C Sester M, Gerog T, Kohler H. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. KI 2002; 62:949-955.
39. Morales JM, Domínguez Gil. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. Journal of Hypertension 2005; 23:1609-1616.
40. Fazelzadeh A, Mehdizadeh AR, Ostovan MA, Raiss-Jalali GA. Predictors of cardiovascular events and associated mortality of kidney transplant recipients.
Transplantation Proceedings 2006; 38:509-511.
41. Wilhelm MJ, Kusaka M, Pratschke J, Tilney NL. Chronic rejection: increasing evidence for the importance of alloantigen independent factors. Transplant Proc 1998; 30:2420.
42. Nolan. Strategies for improving long term survival in patients with ESRD. J Am Soc Nephrol 16:S120-S127.
43. Simon T, Opelz G, Weisel M, Ott RC, Susal C. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection. Am J Transplant 2003; 3:1121-1127.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008